Brand Mucinex, an expectorant for the relief of chest congestion, has $135 million in annual sales.
Perrigo Company (Nasdaq:PRGO; TASE:PRGO) has launched its generic version of Mucinex, an expectorant for the relief of chest congestion. Brand Mucinex has $135 million in annual sales.
Perrigo has begun limited shipments, and plans to begin full-scale over-the-counter deliveries to its retail and wholesale customers in store brand or own label by the end of the company's fiscal year.
Perrigo has NIS 11 billion in annual sales, so Mucinex is immaterial on the company's total revenue, although it adds to the company’s portfolio.
Perrigo's share price fell 0.7% on the TASE today to NIS 387, after rising 0.2% on Nasdaq on Friday to $101.14, giving a market cap of $9.7 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on April 15, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012